Fermer le menu

Lyon, France – July 06, 2023 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced the publication of promising preclinical proof of cross-protection data against multiple SARS-CoV-2 variants with OVX033, its sarbecovirus vaccine candidate, in a hamster challenge model. The research report article was published under the title, “OVX033, a nucleocapsid-based vaccine candidate provides broad-spectrum protection against SARS-CoV-2 variants in a hamster challenge model,” in Volume 14 – 2023 of the journal Frontiers in Immunology.


Read the press release

Plus d'infos